Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
Compass Pathways (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit. The company's management team will engage in a fireside chat on September 26, 2024, at 1:20pm ET.
This event highlights Compass Pathways' involvement in the growing field of psychedelic-based therapies and novel approaches to neuropsychiatry. Interested parties can access a live audio webcast of the chat through the Events page on the Compass website. The recording will remain available for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the discussion.
Compass Pathways (Nasdaq: CMPS), una compagnia biotecnologica focalizzata sull'innovazione nella salute mentale, ha annunciato la sua partecipazione al Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit. Il team di gestione dell'azienda parteciperà a un fireside chat il 26 settembre 2024, alle 13:20 ET.
Questo evento sottolinea il coinvolgimento di Compass Pathways nel crescente campo delle terapie basate su psichedelici e degli approcci innovativi alla neuropsichiatria. Le parti interessate possono accedere a un webcast audio dal vivo della discussione attraverso la pagina Eventi del sito web di Compass. La registrazione rimarrà disponibile per 30 giorni dopo l'evento, offrendo un'opportunità a coloro che non possono partecipare dal vivo di recuperare la discussione.
Compass Pathways (Nasdaq: CMPS), una compañía biotecnológica enfocada en la innovación en salud mental, ha anunciado su participación en el Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit. El equipo de gestión de la empresa participará en un fireside chat el 26 de septiembre de 2024, a la 1:20 p.m. ET.
Este evento destaca la participación de Compass Pathways en el creciente campo de las terapias basadas en psicodélicos y en los enfoques novedosos para la neuropsiquiatría. Las partes interesadas pueden acceder a un webcast de audio en vivo de la charla a través de la página de Eventos en el sitio web de Compass. La grabación estará disponible durante 30 días después del evento, brindando la oportunidad a quienes no puedan asistir en vivo de ponerse al día con la discusión.
컴파스 패스웨이즈 (Nasdaq: CMPS)는 정신 건강 혁신에 중점을 둔 생명공학 회사로서 코웬 환각제와 신경정신의학의 새로운 메커니즘 정상 회담에 참가한다고 발표했습니다. 회사의 경영진 팀은 2024년 9월 26일, 오후 1시 20분 ET에 파이어사이드 차트에 참여할 예정입니다.
이 이벤트는 컴파스 패스웨이즈가 환각제 기반 요법과 신경정신의학에 대한 새로운 접근 방식의 성장하는 분야에 참여하고 있음을 강조합니다. 관심 있는 분들은 컴파스 웹사이트의 이벤트 페이지를 통해 실시간 오디오 웹캐스트에 접속할 수 있습니다. 녹화는 행사 후 30일 동안 이용 가능하며, 실시간으로 참석할 수 없는 분들이 토론 내용을 따라잡을 수 있는 기회를 제공합니다.
Compass Pathways (Nasdaq: CMPS), une entreprise biopharmaceutique axée sur l'innovation en santé mentale, a annoncé sa participation au Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit. L'équipe de direction de la société participera à un fireside chat le 26 septembre 2024 à 13h20 ET.
Cet événement met en lumière l'implication de Compass Pathways dans le domaine en pleine croissance des thérapies basées sur les psychédéliques et des approches novatrices en neuropsychiatrie. Les parties intéressées peuvent accéder à un webcast audio en direct de la discussion via la page Événements du site web de Compass. L'enregistrement restera disponible pendant 30 jours après l'événement, offrant ainsi une occasion à ceux qui ne peuvent pas assister en direct de rattraper la discussion.
Compass Pathways (Nasdaq: CMPS), ein biotechnologisches Unternehmen, das sich auf Innovationen im Bereich psychische Gesundheit konzentriert, hat seine Teilnahme am Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit bekannt gegeben. Das Management-Team des Unternehmens wird am 26. September 2024 um 13:20 Uhr ET an einem Fireside Chat teilnehmen.
Diese Veranstaltung hebt das Engagement von Compass Pathways im wachsenden Bereich der psychedelischen Therapien und neuartigen Ansätze in der Neuropsychiatrie hervor. Interessierte können über die Veranstaltungsseite auf der Compass-Website auf einen Live-Audio-Webcast des Chats zugreifen. Die Aufzeichnung bleibt 30 Tage nach der Veranstaltung verfügbar, was eine Gelegenheit für diejenigen bietet, die nicht live teilnehmen können, um die Diskussion nachzuholen.
- None.
- None.
A live audio webcast of the chat will be available on the Events page of the Compass website and will be archived for 30 days.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are living with mental health challenges and who are not helped by existing standards of care. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the
We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in TRD, the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single 25mg dose of COMP360 psilocybin with psychological support. We have completed an open label phase 2 study of COMP360 psilocybin treatment for post-traumatic stress disorder (PTSD), and we are currently conducting a phase 2 clinical study in anorexia nervosa.
Compass is headquartered in
Availability of other information about Compass Pathways
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923601471/en/
Media: Sally Bain, Sally.Bain@compasspathways.com + 1 781 458 0443
Investors: Stephen Schultz, Stephen.Schultz@compasspathways.com +1 401 290 7324
Source: Compass Pathfinder Limited
FAQ
When is Compass Pathways (CMPS) participating in the Cowen Psychedelics Summit?
How can I watch Compass Pathways' (CMPS) fireside chat at the Cowen Summit?
What is the focus of Compass Pathways (CMPS) as a biotechnology company?
Where is Compass Pathways (CMPS) based?
